Tristel plc
("Tristel" or the
"Company")
Confirmation of CEO Transition and
Directorate Change
Tristel plc (AIM: TSTL), the
manufacturer of infection prevention products, confirms that Matt
Sassone has today assumed his position of CEO of Tristel, following
Paul Swinney's retirement, as previously announced on
10 June 2024.
The Company also announces that Bart
Leemans will step down from the Tristel Board as an Executive
Director. He will remain with the business and continue to focus
his efforts on the French market in his capacity as Managing
Director, Tristel SAS. There are no current plans to replace Bart
on the Tristel Board.
Bart was appointed in November 2018
following Tristel's acquisition of his business, the Ecomed Group,
the Company's then distributor in Belgium, the Netherlands and
France. The French market continues to represent significant
untapped growth potential for the Company; sales in France during
the year ended 30 June 2024 were £3.0 million, approximately 7% of
the Group's total of £41.9 million, compared with 13% of Group
sales generated in Germany and 39% in the UK.
Bruno Holthof, Chair
of Tristel, commented: "I
would like to welcome Matt to our Company, and also thank Bart for
his contribution to the Board during his tenure. He has brought
with him great entrepreneurial spirit and drive and I am pleased
that he will continue to contribute to the growth of the business
through dedicating his efforts to the French market."
For further
information please contact:
Tristel plc
|
Via
Walbrook PR
|
|
Matt Sassone, Chief Executive
Officer
|
www.investors.tristel.com
|
|
Liz Dixon, Chief Financial
Officer
|
|
|
|
|
|
Walbrook PR Ltd
|
Tel: 020
7933 8780 or tristel@walbrookpr.com
|
|
Paul McManus
|
Mob: 07980
541 893
|
|
Charlotte Edgar
|
Mob: 07884 664 686
|
|
|
|
|
Cavendish Capital Markets Limited
|
Tel: 020
7220 0500
|
|
Geoff Nash, Camilla Hume/Trisyia
Jamaludin (Corporate Finance)
|
|
|
Sunila de Silva (Corporate
Broking)
|
|
|
|
| |
The information contained within
this announcement is deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulation ("MAR")
EU no.596/2014. Upon the publication of this announcement via
Regulatory Information Service ("RIS"), this inside information is
now considered to be in the public domain.
About Tristel
plc
Tristel plc is a global infection
prevention company focussed on the manufacture and supply of
products using its unique proprietary chlorine dioxide
(ClO2) chemistry. The Company is a market leader
in manual decontamination of medical devices, supplying
hospitals under the Tristel brand, and under the Cache brand
provides products for sporicidal surface disinfection, in a format
which is a sustainable alternative to commonly used pre-wetted
plastic wipes.
Tristel's head office and manufacturing
facility is located in Snailwell, near Cambridge, and operates
globally employing approximately 250 people across 14 subsidiaries
selling into 40 countries.
The Company has been listed on the London Stock
Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product
range please visit: https://tristel.com.